XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 80 filers reported holding XENON PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,380,166 | -52.5% | 98,951 | -46.5% | 1.11% | -52.7% |
| Q2 2023 | $7,122,500 | -0.5% | 185,000 | -7.5% | 2.35% | +11.1% |
| Q1 2023 | $7,158,000 | +134.2% | 200,000 | +100.0% | 2.12% | +219.2% |
| Q1 2022 | $3,057,000 | -2.1% | 100,000 | 0.0% | 0.66% | -40.8% |
| Q4 2021 | $3,124,000 | -80.3% | 100,000 | -90.4% | 1.12% | -75.9% |
| Q3 2021 | $15,891,000 | +0.4% | 1,040,000 | +22.4% | 4.65% | +6.8% |
| Q2 2021 | $15,827,000 | +4.0% | 850,000 | 0.0% | 4.35% | +21.7% |
| Q1 2021 | $15,215,000 | +41.3% | 850,000 | +21.4% | 3.58% | +49.1% |
| Q4 2020 | $10,766,000 | +199.2% | 700,000 | +115.4% | 2.40% | +130.7% |
| Q3 2020 | $3,598,000 | -11.7% | 325,000 | 0.0% | 1.04% | -3.3% |
| Q2 2020 | $4,076,000 | +10.6% | 325,000 | 0.0% | 1.08% | +9.9% |
| Q1 2020 | $3,686,000 | +514.3% | 325,000 | +116.7% | 0.98% | +773.2% |
| Q1 2017 | $600,000 | -76.0% | 150,000 | -53.8% | 0.11% | -81.4% |
| Q4 2016 | $2,503,000 | -4.9% | 325,000 | 0.0% | 0.60% | +41.0% |
| Q3 2016 | $2,633,000 | +509.5% | 325,000 | +766.7% | 0.43% | +205.0% |
| Q2 2015 | $432,000 | – | 37,500 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |